Piroxicam Betacyclodextrine Manufacturers in India, Suppliers, Piroxicam Betacyclodextrine Exporters, Distributors Piroxicam Betacyclodextrine, api, active pharmaceuticals ingredients, Piroxicam Betacyclodextrine, Symptoms, manufacturers, Side, Effects, Molecular Formula C20H21N3O7S, Molecular Weight 447.46, CAS Registry Number 96684-40-1, bulk drugs, raw material, Generic, Piroxicam Betacyclodextrine companies, Side, Effects, DMF, FDA, Importers Piroxicam Betacyclodextrine, Piroxicam Betacyclodextrine Exporters, Piroxicam Betacyclodextrine exporters, Piroxicam Betacyclodextrine Taj Pharmaceuticals Ltd.

Sitemap | Contact Us

Welcome To Taj Pharmaceuticals Ltd API

© 2004 - 2019 Taj Pharmaceuticals Limited . All rights reserved

Piroxicam Taj API

India

Latin America/ Caribbean

Africa & Middle East

Asia

Russia

Europe

Piroxicam Betacyclodextrine Manufacturers in India Suppliers Piroxicam Betacyclodextrine Exporters Distributors Piroxicam Betacyclodextrine api active pharmaceuticals ingredients Piroxicam Betacyclodextrine manufacturers Side Effects bulk drugs raw material Piroxicam Betacyclodextrine companies Side Effects Importers Piroxicam Betacyclodextrine Piroxicam Betacyclodextrine Exporters Piroxicam Betacyclodextrine exporters FDA Piroxicam Betacyclodextrine DMF Symptoms Generic Taj Pharmaceuticals Ltd.

active pharmaceutical ingredients suppliers pharmaceutical Piroxicam Betacyclodextrine manufacturing pharmaceutical drugs pharmaceutical intermediates Piroxicam Betacyclodextrine pharmaceutical chemicals pharmaceutical raw materials Piroxicam Betacyclodextrine active pharmaceutical ingredients Piroxicam Betacyclodextrine committee active pharmaceutical ingredients manufacturer Piroxicam Betacyclodextrine Active Pharmaceutical Ingredients manufacturer Piroxicam Betacyclodextrine exporter drug ingredients pharmaceuticals

Pharmaceuticals API Manufacturer Piroxicam Betacyclodextrine, Piroxicam Betacyclodextrine manufacturer India, Piroxicam Betacyclodextrine product, Piroxicam Betacyclodextrine products, Api preparation, Certificate of Analysis API manufacturer product, Piroxicam Betacyclodextrine anti ulcer product, Certificate of Origin COA Piroxicam Betacyclodextrine COS Piroxicam Betacyclodextrine, pharmaceutical generic, pharmaceutical drug, medical, Piroxicam Betacyclodextrine pharma healthcare, pharma patents, contract MSDS manufacturing Trader Piroxicam Betacyclodextrine pharma, generic pharma, HCL pharma MSDS pharmaceutical products, pharmaceutical formulations, generic import API, Piroxicam Betacyclodextrine expectorant Pharmaceutical GMP Method of analysis formulations manufacturer, Piroxicam Betacyclodextrine DMF drug master file pharmaceutical Anti Cancer active ingredient exporter from India, pharma Piroxicam Betacyclodextrine ingredients, api, HIV Piroxicam Betacyclodextrine, tablets, capsules, syrup & protein Piroxicam Betacyclodextrine powder, GMP of Plant api nutraceuticals, gynec products, ortho ingredients in India, oncology products, Piroxicam Betacyclodextrine gastroenterology products, buy, sell orthopaedic product, who gmp, cGMP, US FDA, Piroxicam Betacyclodextrine WHO, UKMHRA Approval

	PRODUCT LIST
	Home
	API >>>
	Pharmaceuticals API List
	Chemicals
	Manufacturing
	Product Development
	Product Search
	Agro Chemicals
	Custom Pharma Services
	Contact Us

Pioglitazone Taj API

HOME >> API >> API List 3 >> Piroxicam Betacyclodextrine

Piroxicam Betacyclodextrine CAS Registry Number 96684-40-1

Molecular Structure

Piroxicam Betacyclodextrine

Molecular Formula C20H21N3O7S

Molecular Weight 447.46

CAS Registry Number 96684-40-1

Piroxicam-beta-cyclodextrin is a complex of the established nonsteroidal antiinflammatory drug (NSAID) piroxicam and an inert cyclic macromolecule, beta-cyclodextrin. In clinical trials in patients with rheumatic diseases or pain arising from other conditions, it was as effective an analgesic as standard piroxicam, and showed a faster onset of action on the first day of treatment. In short term pharmacodynamic studies in healthy volunteers, piroxicam-beta-cyclodextrin was equivalent to or tended to show less gastrointestinal mucosal toxicity than standard piroxicam, as assessed by endoscopy and faecal blood loss. However, no data are available on its comparative gastrointestinal mucosal effects from long term clinical trials using similar measures. Preliminary findings from a clinical study suggest piroxicam-beta-cyclodextrin caused fewer gastroduodenal lesions than tenoxicam. As with other NSAIDs, the majority of adverse events associated with piroxicam-beta-cyclodextrin in clinical trials were gastrointestinal in origin, with epigastric pain, heartburn and nausea the most common. Thus, piroxicam-beta-cyclodextrin is an effective agent in patients with rheumatic diseases or other pain states. When rapid analgesia is required in the initial treatment of acute pain, the faster onset of action of piroxicam-beta-cyclodextrin may be an advantage over the parent compound; however, this is unlikely to be important during long term therapy. The results of further long term trials are awaited before firm conclusions can be reached regarding the gastrointestinal tolerability of piroxicam-beta-cyclodextrin compared with that of standard piroxicam and other NSAIDs.

Information Associated with Product:

DRUG DESCRIPTION

DOSAGE

SIDE EFFECTS

PRECAUTIONS

INTERACTION

CONSUMER INFORMATION

PDF DOWNLOAD

WORD DOCUMENT


Product Enquiry	Product Quotation	Sample Request	Place Your Order

Taj Pharmaceuticals API Logo

Api Manufacturer,Export,Supplies,Manufacturing in India

	Investor Relations Feedback Contact Worldwide Sitemap

© 2004 - 2019 Taj Pharmaceuticals Limited . All rights reserved
Note:-We are committed to helping you find the right answers to your questions and concerns. However, this web site is not intended to give investment advice, promote the use of Taj Pharmaceuticals Limited products or provide information on which to base medical treatment. If you have questions regarding any Taj Pharmaceuticals Ltd product or are experiencing a medical emergency, please consult your health care provider.
Additionally, contact information on this web site cannot be used to report adverse drug events. If you are a physician, please follow the procedures required by your country's regulations. Please choose one of the given options to contact us and we will respond to your inquiry as quickly as possible.